Soin Therapeutics receives FDA Orphan Drug Status Grant

Soin Therapeutics receives FDA Orphan Drug Status Grant

The US FDA (Food and Drug Administration) has granted Ohio-based pharmaceutical company Soin Therapeutics orphan drug status for low dose naltrexone (LDN) for the treatment of complex regional pain syndrome (CRPS). Complex Regional Pain Syndrome is characterized by...